Floatz logo

Therapeutic Asset Ratings

13,157 results matching 1 filter

91,583 assets · 7,906 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Obinutuzumab
Primary Mediastinal Large B-Cell Lymphoma
Acepodia Biotech, Inc.P2BB (64)
Olaparib
Non-Hodgkin Lymphoma
OHSU Knight Cancer InstituteP2BB (64)
Olaparib
Central Nervous System Neoplasm
National Cancer Institute (NCI)P2BB (64)
Olaparib
Breast Disorder
AstraZenecaP2BB (64)
Olaparib
Ependymoma
Fundación de investigación HMP2BB (64)
Olaparib
Urothelial Carcinoma
Rahul AggarwalP2BB (64)
Olaparib
Ovarian Disorder
Xiaoxiang ChenP2BB (64)
Olaparib
Prostate Carcinoma
OHSU Knight Cancer InstituteP2BB (64)
Olaparib
Soft Tissue Sarcoma
OHSU Knight Cancer InstituteP2BB (64)
Olaparib
Medulloblastoma
Fundación de investigación HMP2BB (64)
Olaparib
Neuroblastoma
Fundación de investigación HMP2BB (64)
Olaparib
Osteosarcoma
Fundación de investigación HMP2BB (64)
Olaparib
Refractory Malignant Neoplasm
Fundación de investigación HMP2BB (64)
Osimertinib
Adenocarcinoma
Blueprint Medicines CorporationP2BB (64)
OXALIPLATIN
Aggressive B-Cell Non-Hodgkin Lymphoma
Shanghai EpimAb Biotherapeutics Co., Ltd.P2BB (64)
OXALIPLATIN
Head And Neck Squamous Cell Carcinoma
Arcus Biosciences, Inc.P2BB (64)
OXALIPLATIN
Burkitt Lymphoma
AIDS Malignancy ConsortiumP2BB (64)
OXALIPLATIN
MALT Lymphoma
Izidore Lossos, MDP2BB (64)
OXALIPLATIN
Primary Mediastinal Large B-Cell Lymphoma
City of Hope Medical CenterP2BB (64)
OXALIPLATIN
High Grade B-Cell Lymphoma
City of Hope Medical CenterP2BB (64)
OXALIPLATIN
Triple-Negative Breast Carcinoma
PfizerP2BB (64)
Pembrolizumab
Cervical Carcinoma
Mayo ClinicP2BB (64)
Pembrolizumab
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Seda S. ToluP2BB (64)
Pembrolizumab
Hormone Receptor-Positive Breast Cancer
Aminex Therapeutics, Inc.P2BB (64)
Pembrolizumab
Mycosis Fungoides And Variants
University of Michigan Rogel Cancer CenterP2BB (64)
Showing 826 to 850 of 13,157 assets
PreviousPage 34 of 527Next